.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Modern anti-doping laboratories continuously adapt to new pharmacological threats. Consequently, redalsomatropin alfa drug testing has become a priority for regulatory bodies. Redalsomatropin alfa, also known as JR-142, is a recombinant fusion protein. It consists of a 22-kDa human growth hormone (hGH) and human serum albumin (HSA). This design significantly extends its half-life in the body. The drug currently undergoes Phase III clinical development for treating growth hormone deficiency. Its potential misuse in sports stems from the anabolic and lipolytic effects of growth hormone analogues.
Standard immunoassays often struggle to identify long-acting growth hormones (LAGHs). Specifically, researchers evaluated Kit 1 and Kit 2 of the routine rhGH assays used in laboratories. They found that only Kit 2 could recognize the fusion protein. However, the cross-reactivity was significantly lower than that of native hGH. This limitation suggests that athletes using the drug might escape detection if laboratories rely solely on immunoassays. Therefore, developing a more robust detection strategy is vital for maintaining sports integrity.
To address these gaps, scientists developed a qualitative initial testing procedure (ITP). They combined affinity purification with Liquid Chromatography-High Resolution Tandem Mass Spectrometry (LC-HRMS/MS). The process uses magnetic beads conjugated with GHR-Fc for sample extraction. Following extraction, researchers perform tryptic digestion to identify specific protein markers unique to the fusion protein. This method proves highly sensitive and specific. Method validation demonstrated that it detects the drug at concentrations as low as 50 ng/mL.
This advancement offers more than just specific detection of JR-142. The LC-HRMS/MS assay can expand to test multiple LAGHs simultaneously. This scalability enhances the efficiency of anti-doping laboratories worldwide. Furthermore, it creates a significant deterrent against the misuse of synthetic hormones in competitive sports. Clinicians in sports medicine must stay informed about these evolving detection capabilities to ensure compliance and athlete health.
It is a long-acting growth hormone analogue currently in clinical trials. It fuses human growth hormone with human serum albumin to increase its half-life, allowing for less frequent dosing.
The attachment of albumin to the hGH molecule interferes with antibody binding in standard immunoassays. This interference results in significantly reduced cross-reactivity and potential false-negative results.
LC-HRMS/MS identifies the unique peptide sequences of the drug after affinity purification. This method provides high sensitivity and specificity, allowing detection even at low concentrations in biological samples.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional endorsement of specific testing protocols. Refer to the latest local and national guidelines for clinical practice.
References
Walpurgis K et al. Detection of the GH Analogue Redalsomatropin Alfa in Sports Drug Testing: Immunological Approaches and LC-HRMS/MS. Drug Test Anal. 2026 Apr 21. doi: 10.1002/dta.70075. PMID: 42014927.
World Anti-Doping Agency. The 2024 Prohibited List International Standard. WADA-AMA.org. Published January 1, 2024.
JCR Pharmaceuticals. JCR Pharmaceuticals Initiates Phase III Trial of JR-142 in Japan. News Release. December 2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers develop a sensitive LC-HRMS/MS method to detect redalsomatropin alfa, a long-acting growth hormone analogue, overcoming immunoassay limitations....
4 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
